Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of KarXT in CYP2D6 Phenotypes in Healthy Adults
NCT07204418Phase 1Recruiting
- Sponsor
- Karuna Therapeutics
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Primary endpoint: Geometric mean ratio for the area under the concentration-time curve from time zero to 12 hours post morning dose. Started Oct 2025; status: recruiting.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07204418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204418.